IP Library Patent Application 15517973
Patent Application
App. No. 15/517,973

MG STEARATE-BASED COMPOSITE NANOPARTICLES, METHODS OF PREPARATION AND APPLICATIONS

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
15/517,973
Abstract

Disclosed are biocompatible composite nanoparticles and methods of preparing biocompatible composite nanoparticles. Also disclosed ate composite nanoparticles which are biocompatible, biodegradable and have numerous other advantages, and also examples of preparation of the nanoparticles and applications for intracellular delivery.

Claims (16)

1 . A method of preparing one or more magnesium stearate based nanoparticles, comprising:

mixing at least one oil with magnesium stearate based nanoparticles to create a paste-like composition; and

separating the magnesium stearate based nanoparticles from the oil.

2 . The method of claim 1 , further wherein the at least one oil comprises plant oil; and wherein the paste-like composition is stirred to achieve a particle size distribution of the magnesium stearate based nanoparticles.

3 . The method of claim 1 , wherein the separating the magnesium stearate based nanoparticles occurs by at least one method from the following group: filtration, sedimentation, centrifugation, magnetic separation, washing, or any combination thereof.

4 . The method of claim 1 , further comprising incorporating one or more essentially hydrophilic components into the magnesium stearate based nanoparticles.

5 . The method of claim 4 , wherein the one or more hydrophilic components comprises at least one active ingredient, marker, passive ingredient, formulation ingredient, or any combination thereof.

6 . The method of claim 5 , wherein the at least one active ingredient is selected from the group consisting of one or more proteins, peptides, nucleic acids, lipids, amino acids, carbohydrates and derivatives of these aforementioned ingredients, pharmaceutical active ingredients, magnetite, fluorescent markers, and any combination thereof.

7 . The method of claim 5 , wherein the at least one active ingredient is selected from the group consisting of a protein, a humanized monoclonal antibody, a human monoclonal antibody, a chimeric antibody, an immunoglobulin, fragment, derivative or fraction thereof, a synthetic, semi-synthetic or biosynthetic substance mimicking immunoglobulins or fractions thereof, an antigen binding protein or fragment thereof, a fusion protein or peptide or fragment thereof, a receptor antagonist, an antiangiogenic compound, an intracellular signaling inhibitor, a peptide with a molecular mass equal to or higher than 3 kDa, a ribonucleic acid (RNA), a deoxyribonucleic acid (DNA), a plasmid, a peptide nucleic acid (PNA), a steroid, a corticosteroid, an adrenocorticostatic, an antibiotic, an antidepressant, an antimycotic, a [beta]-adrenolytic, an androgen or antiandrogen, an antianemic, an anabolic, an anesthetic, an analeptic, an antiallergic, an antiarrhythmic, an antiarterosclerotic, an antibiotic, an antifibrinolytic, an anticonvulsive, an anti-inflammatory drug, an anticholinergic, an antihistamine, an antihypertensive, an antihypotensive, an anticoagulant, an antiseptic, an antihemorrhagic, an antimyasthenic, an antiphlogistic, an antipyretic, a beta-receptor antagonist, a calcium channel antagonist, a cell differentiation factor, a chemokine, a chemotherapeutic, a co-enzyme, a cytotoxic agent, a prodrug of a cytotoxic agent, a cytostatic, an enzyme and its synthetic or biosynthetic analogue, a glucocorticoid, a growth factor, a hemostatic, a hormone and its synthetic or biosynthetic analogue, an immunosuppressant, an immunostimulant, a mitogen, a physiological or pharmacological inhibitor of mitogens, a mineralocorticoid, a muscle relaxant, a narcotic, a neurotransmitter, a precursor of neurotransmitter, an oligonucleotide, a peptide, a (para)-sympathomimetic, a (para)-sympatholytic, a sedating agent, a spasmolytic, a vasoconstrictor, a vasodilator, a vector, a virus, a virus-like particle, a virustatic, a wound healing substance and a combination thereof.

8 . The method of claim 1 , wherein the nanoparticles are biocompatible, biodegradable and possess superparamagnetic properties.

9 . The method of claim 1 , wherein a sustained intracellular release effect of the nanoparticles is increased compared to a conventional carrier.

10 . The method of claim 1 , wherein the paste-like composition is low in water and oil fractions.

11 . The method of claim 1 , wherein the nanoparticles have average particle diameters ranging from approximately 150 nm to approximately 1000 nm.

12 . The method of claim 1 , wherein the nanoparticles have average particle diameters ranging from approximately 150 nm to approximately 1750 nm.

13 . The method of claim 1 , wherein the nanoparticles provide intracellular delivery of one or more active ingredients.

14 . The method of claim 1 , wherein the at least one oil is selected from the group consisting of tocopherol, castor oil, plant oil, and combinations thereof.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 30, 2018
From: THERAKINE
To: BIOCORRX, INC.
Reel/Frame 047358/0948 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 30, 2018
From: THERAKINE BIODELIVERY GMBH
To: BIOCORRX, INC.
Reel/Frame 047359/0081 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 30, 2018
From: BIOCORRX, INC.
To: BIOCORRX PHARMACEUTICALS, INC.
Reel/Frame 047359/0258 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 18, 2017
From: VOIGT, ANDREAS; LEHMANN, SONJA; ASSOGBA-ZANDT, ANNETTE
To: THERAKINE BIODELIVERY GMBH
Reel/Frame 042038/0740 →